150 related articles for article (PubMed ID: 24767713)
1. Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study.
Gromowski T; Masojć B; Scott RJ; Cybulski C; Górski B; Kluźniak W; Paszkowska-Szczur K; Rozmiarek A; Dębniak B; Maleszka R; Kładny J; Lubiński J; Dębniak T
Cancer Genet; 2014 Apr; 207(4):128-32. PubMed ID: 24767713
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history.
Ghiorzo P; Pastorino L; Queirolo P; Bruno W; Tibiletti MG; Nasti S; Andreotti V; ; Paillerets BB; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2013 Mar; 26(2):259-62. PubMed ID: 23167872
[TBL] [Abstract][Full Text] [Related]
4. Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients.
Vergani E; Frigerio S; Dugo M; Devecchi A; Feltrin E; De Cecco L; Vallacchi V; Cossa M; Di Guardo L; Manoukian S; Peissel B; Ferrari A; Gallino G; Maurichi A; Rivoltini L; Sensi M; Rodolfo M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573422
[TBL] [Abstract][Full Text] [Related]
5. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
Bertolotto C; Lesueur F; Giuliano S; Strub T; de Lichy M; Bille K; Dessen P; d'Hayer B; Mohamdi H; Remenieras A; Maubec E; de la Fouchardière A; Molinié V; Vabres P; Dalle S; Poulalhon N; Martin-Denavit T; Thomas L; Andry-Benzaquen P; Dupin N; Boitier F; Rossi A; Perrot JL; Labeille B; Robert C; Escudier B; Caron O; Brugières L; Saule S; Gardie B; Gad S; Richard S; Couturier J; Teh BT; Ghiorzo P; Pastorino L; Puig S; Badenas C; Olsson H; Ingvar C; Rouleau E; Lidereau R; Bahadoran P; Vielh P; Corda E; Blanché H; Zelenika D; Galan P; ; Aubin F; Bachollet B; Becuwe C; Berthet P; Bignon YJ; Bonadona V; Bonafe JL; Bonnet-Dupeyron MN; Cambazard F; Chevrant-Breton J; Coupier I; Dalac S; Demange L; d'Incan M; Dugast C; Faivre L; Vincent-Fétita L; Gauthier-Villars M; Gilbert B; Grange F; Grob JJ; Humbert P; Janin N; Joly P; Kerob D; Lasset C; Leroux D; Levang J; Limacher JM; Livideanu C; Longy M; Lortholary A; Stoppa-Lyonnet D; Mansard S; Mansuy L; Marrou K; Matéus C; Maugard C; Meyer N; Nogues C; Souteyrand P; Venat-Bouvet L; Zattara H; Chaudru V; Lenoir GM; Lathrop M; Davidson I; Avril MF; Demenais F; Ballotti R; Bressac-de Paillerets B
Nature; 2011 Oct; 480(7375):94-8. PubMed ID: 22012259
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia.
Gupta S; Erickson LA; Lohse CM; Shen W; Pitel BA; Knight SM; Halling KC; Herrera-Hernandez L; Boorjian SA; Thompson RH; Leibovich BC; Jimenez RE; Cheville JC
JAMA Netw Open; 2021 Nov; 4(11):e2132615. PubMed ID: 34767027
[TBL] [Abstract][Full Text] [Related]
7. Cancer risks associated with the germline MITF(E318K) variant.
Guhan SM; Artomov M; McCormick S; Njauw C-; Stratigos AJ; Shannon K; Ellisen LW; Tsao H
Sci Rep; 2020 Oct; 10(1):17051. PubMed ID: 33051548
[TBL] [Abstract][Full Text] [Related]
8. The lack of E318K MITF germline mutation in Latvian melanoma patients.
Ozola A; Pjanova D
Cancer Genet; 2015 Jun; 208(6):355-6. PubMed ID: 25975176
[No Abstract] [Full Text] [Related]
9. Vulvar Melanoma in association with germline MITF p.E318K variant.
Koeller DR; Schwartz A; DeSimone MS; Rana HQ; Rojas-Rudilla V; Russell-Goldman E; Laga AC; Lindeman NI; Garber JE; Ghazani AA
Cancer Genet; 2022 Apr; 262-263():102-106. PubMed ID: 35220194
[TBL] [Abstract][Full Text] [Related]
10. The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma.
Castro-Vega LJ; Kiando SR; Burnichon N; Buffet A; Amar L; Simian C; Berdelou A; Galan P; Schlumberger M; Bouatia-Naji N; Favier J; Bressac-de Paillerets B; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2016 Dec; 101(12):4764-4768. PubMed ID: 27680874
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients.
Sturm RA; Fox C; McClenahan P; Jagirdar K; Ibarrola-Villava M; Banan P; Abbott NC; Ribas G; Gabrielli B; Duffy DL; Peter Soyer H
J Invest Dermatol; 2014 Jan; 134(1):141-149. PubMed ID: 23774529
[TBL] [Abstract][Full Text] [Related]
12. The Microphthalmia-Associated Transcription Factor p.E318K Mutation Does Not Play a Major Role in Sporadic Renal Cell Tumors from Caucasian Patients.
Stoehr CG; Walter B; Denzinger S; Ghiorzo P; Sturm RA; Hinze R; Moch H; Junker K; Hartmann A; Stoehr R
Pathobiology; 2016; 83(4):165-9. PubMed ID: 26999813
[TBL] [Abstract][Full Text] [Related]
13. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
14. The MC1R r allele does not increase melanoma risk in MITF E318K carriers.
Wallingford CK; Demeshko A; Krishnakripa AK; Smit DJ; Duffy DL; Betz-Stablein B; Pflugfelder A; Jagirdar K; Holland E; Mann GJ; Primiero CA; Yanes T; Malvehy J; Badenas C; Carrera C; Aguilera P; Olsen CM; Ward SV; Haass NK; Sturm RA; Puig S; Whiteman DC; Law MH; Cust AE; Potrony M; Soyer HP; McInerney-Leo AM
Br J Dermatol; 2023 May; 188(6):770-776. PubMed ID: 36879448
[TBL] [Abstract][Full Text] [Related]
15. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
16. A germline oncogenic MITF mutation and tumor susceptibility.
Paillerets BB; Lesueur F; Bertolotto C
Eur J Cell Biol; 2014; 93(1-2):71-5. PubMed ID: 24290354
[TBL] [Abstract][Full Text] [Related]
17. Expanding the phenotype of E318K (c.952G > A) MITF germline mutation carriers: case series and review of the literature.
Oliveira LJC; Gongora ABL; Lima FAS; Canedo FSNA; Quirino CV; Pisani JP; Achatz MI; Rossi BM
Hered Cancer Clin Pract; 2021 Jul; 19(1):32. PubMed ID: 34289891
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of bias in familial risk estimates: a study of common cancers using Swedish population-based registers.
Leu M; Reilly M; Czene K
J Natl Cancer Inst; 2008 Sep; 100(18):1318-25. PubMed ID: 18780865
[TBL] [Abstract][Full Text] [Related]
19. Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients.
Ciccarese G; Dalmasso B; Bruno W; Queirolo P; Pastorino L; Andreotti V; Spagnolo F; Tanda E; Ponti G; Massone C; Drago F; Parodi A; Ghigliotti G; Pizzichetta MA; Ghiorzo P;
J Transl Med; 2020 Feb; 18(1):78. PubMed ID: 32054529
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland.
Debniak T; van de Wetering T; Scott R; Nagay L; Cybulski C; Górski B; Jakubowska A; Gronwald J; Masojć B; Huzarski T; Byrski T; Nej-Wołosiak K; Kładny J; Maleszka R; Lubinski J
Eur J Cancer Prev; 2008 Oct; 17(5):389-91. PubMed ID: 18714178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
